Hepatic resection for recurrent metastatic ovarian cancer - 20/08/11
Corresponding author. Tel.: +1-708-327-3430; fax: +1-708-327-3565.Abstract |
Background |
The role for liver resection in metastatic ovarian cancer has not been defined. The aim of the current study was to investigate the validity of hepatic resection as a treatment option in metastatic ovarian cancer.
Methods |
Retrospective review of a single institution’s experience of patients undergoing hepatic resection for metastatic ovarian cancer from 1998–2006.
Results |
Ten patients underwent resection for metastatic ovarian cancer. Primary tumor type included serous cystadenocarcinoma (n = 8), granulosa cell (n = 1), and yolk sac (n = 1). Median disease-free interval was 48 months. Liver resections included trisegmentectomy (n = 4), lobectomy (n = 4), and bisegmentectomy(n = 1). Additional surgeries included diaphragm resection (n = 60), bowel resection, (n = 30), and adrenalectomy (n = 10). The median overall survival following liver resection was 33 months.
Conclusion |
Liver resection for metastatic ovarian cancer is safe and is associated with long-term survival in some patients. Larger analysis may lead to the identification of prognostic factors associated with improved outcomes.
Le texte complet de cet article est disponible en PDF.Keywords : Liver resection, Recurrent ovarian cancer, Survival
Plan
Vol 195 - N° 3
P. 370-373 - mars 2008 Retour au numéro
Article précédent
- Melanoma adrenal metastasis: natural history and surgical management
- Elizabeth A. Mittendorf, Sherry J. Lim, Chris W. Schacherer, Anthony Lucci, Janice N. Cormier, Paul F. Mansfield, Jeffrey E. Gershenwald, Merrick I. Ross, Jeffrey E. Lee
- Does homocysteine contribute to bone disease in hyperparathyroidism?
- Robin A. Alley, Emery L. Chen, Todd D. Beyer, Richard A. Prinz
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?